Denali Therapeutics (NASDAQ: DNLI) insider to sell 35,198 shares

Rhea-AI Filing Summary

A shareholder of Denali Therapeutics Inc. has filed a notice of proposed sale under Rule 144 covering 35,198 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or about 01/06/2026 on the NASDAQ, with an aggregate market value listed as $580,767. The filing notes that these shares were acquired on 01/03/2026 through a restricted stock lapse described as equity compensation.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 38th Fl. New York NY 10004	35198	580767	156182177	01/06/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/03/2026	Restricted Stock Lapse - See Remarks	Denali Therapeutics Inc.			35198	01/03/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Denali Therapeutics (DNLI) shares are planned to be sold in this Form 144?

The notice covers a proposed sale of 35,198 shares of Denali Therapeutics Inc. common stock.

What is the aggregate market value of the DNLI shares in this Form 144 filing?

The filing states an aggregate market value for the planned sale of $580,767.

On which exchange and through which broker will the DNLI shares be sold?

The shares are to be sold on the NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 38th Floor, New York, NY 10004.

When were the DNLI shares to be sold under this Form 144 acquired?

The 35,198 shares were acquired on 01/03/2026 via a restricted stock lapse described as equity compensation.

What does the Rule 144 representation in this DNLI filing state?

The person for whose account the securities are to be sold represents by signing that they do not know any material adverse information about Denali Therapeutics Inc.'s current or prospective operations that has not been publicly disclosed.

What class of Denali Therapeutics securities is covered by this Form 144?

The notice relates to the sale of common stock of Denali Therapeutics Inc.